Floatz logo

NEPENTHE

Other Specified Disorders of Kidney and Ureter

Hans BahlmannSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Other Specified Disorders of Kidney and Ureter cohort.

Asset / SponsorPhaseRating
Rocuronium
Rainer Lenhardt
Phase 4BB
LEUPROLIDE
University College, London
Phase 3BB
Zoladex
University College, London
Phase 3BB
Zoledronate
Alliance for Clinical Trials in Oncology
Phase 3B
Casodex
University College, London
Phase 3B

View all 17 →

Same molecule, other indications

NEPENTHE is also rated in:

PainDormant
BBB
Indicative ·
77 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
75 / 100
View asset →
chronic pain syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →